As pro‐tumorigenic TGF‐β and AKT/mTOR signaling pathways were driven by CLTC in osteosarcoma, our study also encourages the development of TGF‐β inhibitors and AKT inhibitors for osteosarcoma therapy. This evidence concerns the gene AKT1 and osteosarcoma.